The Hypertriglyceridemia drugs in development market research report provides comprehensive information on the therapeutics under development for Hypertriglyceridemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypertriglyceridemia. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Hypertriglyceridemia - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued products.

GlobalData tracks 42 drugs in development for Hypertriglyceridemia by 34 companies/universities/institutes. The top development phase for Hypertriglyceridemia is preclinical with 13 drugs in that stage. The Hypertriglyceridemia pipeline has 39 drugs in development by companies and three by universities/ institutes. Some of the companies in the Hypertriglyceridemia pipeline products market are: Sirnaomics, Ionis Pharmaceuticals and MediciNova.

The key targets in the Hypertriglyceridemia pipeline products market include Apolipoprotein C III (APOC3), Angiopoietin Related Protein 3 (Angiopoietin 5 or Angiopoietin Like Protein 3 or ANG 5 or ANGPTL3), and Peroxisome Proliferator Activated Receptor Alpha (Nuclear Receptor Subfamily 1 Group C Member 1 or NR1C1 or PPARA).

The key mechanisms of action in the Hypertriglyceridemia pipeline product include Apolipoprotein C III (APOC3) Inhibitor with seven drugs in Phase III. The Hypertriglyceridemia pipeline products include three routes of administration with the top ROA being Oral and eight key molecule types in the Hypertriglyceridemia pipeline products market including Small Molecule, and Antisense RNAi Oligonucleotide.

Hypertriglyceridemia overview

Hypertriglyceridemia is a condition in which the blood contains high levels of triglycerides, a type of fat that provides energy to the body. Triglycerides are important for normal metabolism, but excess amounts can increase the risk of cardiovascular diseases, such as atherosclerosis, coronary artery disease, and stroke. Hypertriglyceridemia can also cause acute pancreatitis, a serious inflammation of the pancreas that requires medical attention. Hypertriglyceridemia can be caused by genetic factors, obesity, diabetes, sedentary lifestyle, alcohol consumption, and certain medications. The diagnosis is based on a blood test that measures the fasting triglyceride level. A normal level is below 150 mg/dL, while a very high level is above 500 mg/dL. The treatment of hypertriglyceridemia involves lifestyle modifications, such as weight loss, exercise, dietary changes, and alcohol reduction. In some cases, medication may be prescribed to lower the triglyceride level and prevent complications.

For a complete picture of Hypertriglyceridemia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.